期刊文献+

黛力新辅助治疗质子泵抑制剂治疗无效的非糜烂性反流病 被引量:4

Auxiliary therapy with Deanxit in patients of non-erosive reflux disease non-responding to proton pump inhibitor
下载PDF
导出
摘要 目的观察黛力新辅助治疗质子泵抑制剂治疗无效的非糜烂性反流病(NERD)的疗效。方法64例患者按就诊顺序随机分为两组,对照组32例予雷贝拉唑10mg,每日2次;法莫替丁40mg,每晚1次。治疗组32例在对照组治疗基础上加用黛力新1粒,每天早上、中午各1次,治疗4周后进行疗效对比。结果治疗组总有效率81.3%,明显优于对照组62.5%(P<0.05)。结论黛力新辅助雷贝拉唑、法莫替丁对质子泵抑制剂治疗无效的非糜烂性反流病有效。 Objective To observe the effectiveness of auxiliary therapy with Deanxit in patients of non-erosive reflux disease (NERD) who did not respond to proton pump inhibitor. Methods Sixty four NERD patients were randomly divided into two groups: the treatment group (n=32) and control group (n=32). Patients in control group were given with Raheprazole 10mg twice a day, Famotidine 40mg every night. Patients in the treatment group were given the same drugs plus Deanxit (one tablet every morning and noon). The clinical outcomes of two groups were compared after 4 weeks. Results The effective rate in treatment group was 81.3%, while that was 62.5% in control group (P〈0.05). Conclusion Auxiliary therapy of Deanxit combined with Rabeprazole and Famotidine is effective to NERD patients who did not respond to proton pump inhibitor.
出处 《浙江医学》 CAS 2007年第6期527-528,531,共3页 Zhejiang Medical Journal
关键词 非糜烂性反流病 辅助治疗 黛力新 Non-erosive reflux disease Auxiliary therapy Dy Deanxit
  • 相关文献

参考文献6

二级参考文献64

  • 1Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology, 1998,115 : 1335-1339.
  • 2Xue S, Katz PO, Banerjee P, et al. Bedtime Hz blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther, 2001,15 : 1351-1356.
  • 3Nzeako UC, Murray JA. An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther, 2002,16 : 1309-1316.
  • 4Hatlebakk JG, Katz PO, Camacho-Lobato L, et al. Proton pump inhibitors: better acid suppression when taken be[ore a meal than without a meal. Aliment Pharmacol Ther, 2000,14:1267-1272.
  • 5Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology, 2002,122 :625-632.
  • 6Bruley des Varannes S, Shi G, Scarpignato C, et al. Sensitivity to acid and distension in gastro-oesophageal refluc disease(GORD) and the acid hypersensitive oesophagus. Gut, 1996, 39 (Suppl 3):A182.?A
  • 7Villanacci V, Grigolato PG, Cestari R, et al. Dilated intercellular spaces as markers of reflux disease: histology, semiquantitative score and morphometry upon light microscopy. Digestion, 2001, 64:1-8.?A
  • 8Johnsson F, Hatlebakk JG, Klintenberg AC, et al. Symptom-relieving effect of esomeprazole 40mg daily in patients with heartburn.Scand J Gastroenterol, 2003, 38:347-353.?A
  • 9Numans ME, Lau J, Wit NJ, et al. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease. Ann Intern Med, 2004, 140:518-527.?A
  • 10Fock KM, Talley N, Hunt R, et al. Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol, 2004, 19:357-367.?A

共引文献94

同被引文献72

引证文献4

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部